Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie (Q33884167)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

S. Vincent Rajkumar

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Rhett P. Ketterling

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Angela Dispenzieri

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

5

object named as

Morie A Gertz

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

8

object named as

Martha Q Lacy

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Francis K Buadi

11

object named as

Francis Buadi

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

16

object named as

Shaji Kumar

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

12

object named as

Robert A Kyle

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Thomas E. Witzig

13

object named as

Thomas E Witzig

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Prashant Kapoor

1

object named as

Prashant Kapoor

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

P Leif Bergsagel

7

object named as

P Leif Bergsagel

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Philip R. Greipp

14

object named as

Philip R Greipp

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Shirshendu Sinha

4

object named as

Shirshendu Sinha

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

A Keith Stewart

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

David D Dingli

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

language of work or name

0 references

publication date

1 June 2010

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

85

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

532-537

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2878257

5 July 2018

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2878257

5 July 2018

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2878257

5 July 2018

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2878257

5 July 2018

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2878257

5 July 2018

Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2878257

5 July 2018

Role of genetics in prognostication in myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2878257

5 July 2018

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2878257

5 July 2018

Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2878257

5 July 2018

The molecular classification of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2878257

5 July 2018

International staging system for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2878257

5 July 2018

Review of 1027 patients with newly diagnosed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2878257

5 July 2018

A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2878257

5 July 2018

Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2878257

5 July 2018

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2878257

29 October 2018

High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2878257

29 October 2018

Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2878257

29 October 2018

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2878257

29 October 2018

Plasma cell labeling index

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2878257

29 October 2018

Genetics and cytogenetics of multiple myeloma: a workshop report.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2878257

29 October 2018

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2878257

29 October 2018

An internationally recognized uniform cytogenetic classification system is needed for multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20511484

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/20511484

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated

1 reference

https://pubmed.ncbi.nlm.nih.gov/20511484

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytogenetic Abnormalities Correlate with the Plasma Cell Labeling Index and Extent of Bone Marrow Involvement in Myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20511484

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20511484

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20511484

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4065/MCP.2009.0677

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20511484%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33884167&oldid=2080110318"